These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 22208675

  • 1. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
    Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van Ryn J, Lehr T.
    Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
    [Abstract] [Full Text] [Related]

  • 2. The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
    Renda G, De Caterina R.
    Vascul Pharmacol; 2013 Feb; 59(3-4):53-62. PubMed ID: 23872195
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
    Mack DR, Kim JJ.
    Ann Pharmacother; 2012 Feb; 46(7-8):1105-10. PubMed ID: 22764329
    [Abstract] [Full Text] [Related]

  • 4. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 5. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 31; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 6. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM, Qureshi AI.
    Expert Opin Pharmacother; 2010 Jun 31; 11(8):1403-11. PubMed ID: 20446854
    [Abstract] [Full Text] [Related]

  • 7. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C, Barrios V, Jimenez D.
    Cardiovasc Ther; 2010 Oct 31; 28(5):295-301. PubMed ID: 20718760
    [Abstract] [Full Text] [Related]

  • 8. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J, Giroud M, de Pouvourville G.
    Cerebrovasc Dis; 2013 Oct 31; 35(4):320-6. PubMed ID: 23615428
    [Abstract] [Full Text] [Related]

  • 9. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.
    J Stroke Cerebrovasc Dis; 2012 Apr 31; 21(3):165-73. PubMed ID: 22440950
    [Abstract] [Full Text] [Related]

  • 10. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV.
    Thromb Haemost; 2012 Oct 31; 108(4):672-82. PubMed ID: 22898892
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
    Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J.
    J Clin Pharmacol; 2012 Sep 31; 52(9):1373-8. PubMed ID: 21956604
    [Abstract] [Full Text] [Related]

  • 12. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
    Fieland D, Taylor M.
    Ann Pharmacother; 2012 Jan 31; 46(1):e3. PubMed ID: 22202498
    [Abstract] [Full Text] [Related]

  • 13. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators.
    J Am Coll Cardiol; 2014 Feb 04; 63(4):321-8. PubMed ID: 24076487
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
    Hughes PJ, Freeman MK.
    Consult Pharm; 2012 Jun 04; 27(6):445-52. PubMed ID: 22698551
    [Abstract] [Full Text] [Related]

  • 15. [Dabigatran, a new oral anticoagulant].
    Uchiyama S.
    Brain Nerve; 2011 Apr 04; 63(4):411-5. PubMed ID: 21441645
    [Abstract] [Full Text] [Related]

  • 16. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.
    Circulation; 2013 Jul 16; 128(3):237-43. PubMed ID: 23770747
    [Abstract] [Full Text] [Related]

  • 17. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
    Bovio JA, Smith SM, Gums JG.
    Ann Pharmacother; 2011 May 16; 45(5):603-14. PubMed ID: 21540406
    [Abstract] [Full Text] [Related]

  • 18. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.
    Thromb Haemost; 2013 Feb 16; 109(2):328-36. PubMed ID: 23179181
    [Abstract] [Full Text] [Related]

  • 19. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW, Zimetbaum PJ.
    Expert Rev Cardiovasc Ther; 2013 Nov 16; 11(11):1461-71. PubMed ID: 24147516
    [Abstract] [Full Text] [Related]

  • 20. [Waiting for the new oral anticoagulants: questions and answers about dabigatran].
    Verdecchia P, Agnelli G.
    G Ital Cardiol (Rome); 2013 Jan 16; 14(1):35-45. PubMed ID: 23258203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.